Danazol is preferred for refractory autoimmune haemolytic anaemia

&NA;
In: Inpharma Weekly · 1990 · vol. &NA;(720) , pp. 16 · doi:10.2165/00128413-199007200-00042 · W4255687504
OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by qwen3.7-flash, 2026-09-05 ⓘ

The provided text identifies Danazol as the preferred treatment for refractory autoimmune haemolytic anaemia but contains no abstract or details linking these findings to endometriosis or adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T11:01:47.225666+00:00
unpaywall
last seen: 2026-10-18T06:28:46.490043+00:00
License: CC0 · commercial use OK